IniciGrupsConversesExploraTendències
Cerca al lloc
Aquest lloc utilitza galetes per a oferir els nostres serveis, millorar el desenvolupament, per a anàlisis i (si no has iniciat la sessió) per a publicitat. Utilitzant LibraryThing acceptes que has llegit i entès els nostres Termes de servei i política de privacitat. L'ús que facis del lloc i dels seus serveis està subjecte a aquestes polítiques i termes.
Hide this

Resultats de Google Books

Clica una miniatura per anar a Google Books.

S'està carregant…

Bad Blood: Secrets and Lies in a Silicon Valley Startup (2018)

de John Carreyrou

Altres autors: Mira la secció altres autors.

MembresRessenyesPopularitatValoració mitjanaMencions
2,0641496,375 (4.29)90
"The full inside story of the breathtaking rise and shocking collapse of a multibillion-dollar startup, by the prize-winning journalist who first broke the story and pursued it to the end in the face of pressure and threats from the CEO and her lawyers. In 2014, Theranos founder and CEO Elizabeth Holmes was widely seen as the female Steve Jobs: a brilliant Stanford dropout whose startup "unicorn" promised to revolutionize the medical industry with a machine that would make blood tests significantly faster and easier. Backed by investors such as Larry Ellison and Tim Draper, Theranos sold shares in a fundraising round that valued the company at $9 billion, putting Holmes's worth at an estimated $4.7 billion. There was just one problem: The technology didn't work. For years, Holmes had been misleading investors, FDA officials, and her own employees. When Carreyrou, working at The Wall Street Journal, got a tip from a former Theranos employee and started asking questions, both Carreyrou and the Journal were threatened with lawsuits. Undaunted, the newspaper ran the first of dozens of Theranos articles in late 2015. By early 2017, the company's value was zero and Holmes faced potential legal action from the government and her investors. Here is the riveting story of the biggest corporate fraud since Enron, a disturbing cautionary tale set amid the bold promises and gold-rush frenzy of Silicon Valley"-- "The full inside story of the breathtaking rise and shocking collapse of Theranos--the Enron of Silicon Valley--by the prize-winning journalist who first broke the story and pursued it to the end in the face of pressure and threats from the CEO and her lawyers. In 2014, Theranos founder and CEO Elizabeth Holmes was widely seen as the female Steve Jobs: a brilliant Stanford dropout whose startup "unicorn" promised to revolutionize the medical industry with a machine that would make blood tests significantly faster and easier. Backed by investors such as Larry Ellison and Tim Draper, Theranos sold shares in an early fundraising round that valued the company at $9 billion, putting Holmes's worth at an estimated $4.7 billion. There was just one problem: the technology didn't work. For years, Holmes had been misleading investors, FDA officials, and her own employees. When Carreyrou, working at the Wall Street Journal, got a tip from a former Theranos employee and started asking questions, both Carreyrou and the Journal were threatened with lawsuits. Undaunted, the newspaper ran the first of dozens of Theranos articles in late 2015. By early 2017, the company's value was zero and Holmes faced potential legal action from the government and her investors. Here is the riveting story of the biggest corporate fraud since Enron, a disturbing cautionary tale set amid the bold promises and gold-rush frenzy of Silicon Valley"--… (més)
Afegit fa poc persbep, alvitoc, titoCA321, biblioteca privada, KaiStarkk, TashMason, LenihanLimerick
S'està carregant…

Apunta't a LibraryThing per saber si aquest llibre et pot agradar.

No hi ha cap discussió a Converses sobre aquesta obra.

» Mira també 90 mencions

Es mostren 1-5 de 147 (següent | mostra-les totes)
I had no intention of reading this book. I thought I had a good idea about the situation. I had read headlines and a few articles. I had watched the implosion of Theranos at its later stages from a distance in trade magazines. But, when my fellow reading friends kept harping about this book, I decided to finally pick it up.

Carreyrou took what I thought to be your garden variety white-collar crime and turned this into a jaw-dropping page turner. Although dense with detail, intrigue and bat-shit craziness, this was still readable and totally compelling. ( )
  MC_Rolon | Jun 15, 2022 |
Book Prompt: Read a business book.

This was a good introduction to the Theranos scandal. I knew extraordinarily little about what occurred with this medical tech company, so was very curious to find out more. Floored at how easily Elizabeth Holms was able to pull the wool over big companies like Safeway and Walgreens. Also disgusted with how easily and quickly they were willing to bully and intimidate those who wanted the truth out there. Not only did the false claims and the quickness in which they tried to rush products to the market endanger many people, but they had no guilt over the dangers this could cause. The build the plane as we fly it approach is not one that works well for medical tech. I am very interested in watching the several documentaries and limited series shows that are coming out about this. I did feel that the story as told is a bit repetitive in some chapters, going over the same instances more than once. Otherwise, an incredibly informative read, filled with useful information. I recommend it to anyone looking to learn more about this. ( )
  BuffyCharpentier | May 15, 2022 |
Listened on Audible. First 75% was dry as a bone, and made all the more tedious by the narrator's dry delivery. Could've been much shorter. ( )
  dan.chilton | May 12, 2022 |
Only gripe I really had while reading is that multiple acronyms would be introduced early on in the 1st half of the book and I'd forget their meanings when they were then used in the 2nd half. Main one being CLIA-clinical laboratory improvement amendments.

Also I'm not a big nonfiction reader as I struggle to keep focused especially around the midway point but one's written by journalists like this one & Jon Ronson's The Psychopath Test, I've throughly enjoyed mostly due to their writing style. They feel as if they're written by common folk for common folk in which they always explain enough but give ways for the reader to search up more if needed/wanted. ( )
  Wybie | May 8, 2022 |
Incredible, insane story. So glad I don’t work at a startup like this one, toxic to say the least ( )
  ds_db | Apr 25, 2022 |
Es mostren 1-5 de 147 (següent | mostra-les totes)
The author’s description of Holmes as a manic leader who turned coolly hostile when challenged is ripe material for a psychologist; Carreyrou wisely lets the evidence speak for itself. As presented here, Holmes harbored delusions of grandeur but couldn’t cope with the messy realities of bioengineering. Swathed in her own reality distortion field, she dressed in black turtlenecks to emulate her idol Jobs and preached that the Theranos device was “the most important thing humanity has ever built.” Employees were discouraged from questioning this cultish orthodoxy by her “ruthlessness” and her “culture of fear.” Secrecy was obsessive. Labs and doors were equipped with fingerprint scanners.
 

» Afegeix-hi altres autors

Nom de l'autorCàrrecTipus d'autorObra?Estat
John Carreyrouautor primaritotes les edicionscalculat
Damron, WillNarradorautor secundarialgunes edicionsconfirmat
Has d'iniciar sessió per poder modificar les dades del coneixement compartit.
Si et cal més ajuda, mira la pàgina d'ajuda del coneixement compartit.
Títol normalitzat
Informació del coneixement compartit en anglès. Modifica-la per localitzar-la a la teva llengua.
Títol original
Títols alternatius
Data original de publicació
Gent/Personatges
Informació del coneixement compartit en anglès. Modifica-la per localitzar-la a la teva llengua.
Llocs importants
Informació del coneixement compartit en anglès. Modifica-la per localitzar-la a la teva llengua.
Esdeveniments importants
Informació del coneixement compartit en anglès. Modifica-la per localitzar-la a la teva llengua.
Pel·lícules relacionades
Informació del coneixement compartit en anglès. Modifica-la per localitzar-la a la teva llengua.
Premis i honors
Informació del coneixement compartit en anglès. Modifica-la per localitzar-la a la teva llengua.
Epígraf
Dedicatòria
Informació del coneixement compartit en anglès. Modifica-la per localitzar-la a la teva llengua.
For Molly, Sebastian, Jack, and Francesca
Primeres paraules
Informació del coneixement compartit en anglès. Modifica-la per localitzar-la a la teva llengua.
Tim Kemp had good news for his team.
Citacions
Darreres paraules
Informació del coneixement compartit en anglès. Modifica-la per localitzar-la a la teva llengua.
(Clica-hi per mostrar-ho. Compte: pot anticipar-te quin és el desenllaç de l'obra.)
Nota de desambiguació
Editor de l'editorial
Creadors de notes promocionals a la coberta
Informació del coneixement compartit en anglès. Modifica-la per localitzar-la a la teva llengua.
Llengua original
Informació del coneixement compartit en anglès. Modifica-la per localitzar-la a la teva llengua.
CDD/SMD canònics
LCC canònic

Referències a aquesta obra en fonts externes.

Wikipedia en anglès

Cap

"The full inside story of the breathtaking rise and shocking collapse of a multibillion-dollar startup, by the prize-winning journalist who first broke the story and pursued it to the end in the face of pressure and threats from the CEO and her lawyers. In 2014, Theranos founder and CEO Elizabeth Holmes was widely seen as the female Steve Jobs: a brilliant Stanford dropout whose startup "unicorn" promised to revolutionize the medical industry with a machine that would make blood tests significantly faster and easier. Backed by investors such as Larry Ellison and Tim Draper, Theranos sold shares in a fundraising round that valued the company at $9 billion, putting Holmes's worth at an estimated $4.7 billion. There was just one problem: The technology didn't work. For years, Holmes had been misleading investors, FDA officials, and her own employees. When Carreyrou, working at The Wall Street Journal, got a tip from a former Theranos employee and started asking questions, both Carreyrou and the Journal were threatened with lawsuits. Undaunted, the newspaper ran the first of dozens of Theranos articles in late 2015. By early 2017, the company's value was zero and Holmes faced potential legal action from the government and her investors. Here is the riveting story of the biggest corporate fraud since Enron, a disturbing cautionary tale set amid the bold promises and gold-rush frenzy of Silicon Valley"-- "The full inside story of the breathtaking rise and shocking collapse of Theranos--the Enron of Silicon Valley--by the prize-winning journalist who first broke the story and pursued it to the end in the face of pressure and threats from the CEO and her lawyers. In 2014, Theranos founder and CEO Elizabeth Holmes was widely seen as the female Steve Jobs: a brilliant Stanford dropout whose startup "unicorn" promised to revolutionize the medical industry with a machine that would make blood tests significantly faster and easier. Backed by investors such as Larry Ellison and Tim Draper, Theranos sold shares in an early fundraising round that valued the company at $9 billion, putting Holmes's worth at an estimated $4.7 billion. There was just one problem: the technology didn't work. For years, Holmes had been misleading investors, FDA officials, and her own employees. When Carreyrou, working at the Wall Street Journal, got a tip from a former Theranos employee and started asking questions, both Carreyrou and the Journal were threatened with lawsuits. Undaunted, the newspaper ran the first of dozens of Theranos articles in late 2015. By early 2017, the company's value was zero and Holmes faced potential legal action from the government and her investors. Here is the riveting story of the biggest corporate fraud since Enron, a disturbing cautionary tale set amid the bold promises and gold-rush frenzy of Silicon Valley"--

No s'han trobat descripcions de biblioteca.

Descripció del llibre
Sumari haiku

Cobertes populars

Dreceres

Valoració

Mitjana: (4.29)
0.5
1 8
1.5
2 7
2.5 1
3 67
3.5 29
4 263
4.5 60
5 309

Ets tu?

Fes-te Autor del LibraryThing.

 

Quant a | Contacte | LibraryThing.com | Privadesa/Condicions | Ajuda/PMF | Blog | Botiga | APIs | TinyCat | Biblioteques llegades | Crítics Matiners | Coneixement comú | 171,707,326 llibres! | Barra superior: Sempre visible